SCHEMBL15116297

SCHEMBL15116297

O=C(Nc1ccc(S(=O)(=O)Nc2nccs2)cc1)c1cccnc1

nearest known ligand 0.81

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.81
POLB P06746 3/20 0.70
MEN1 O00255 9/20 0.69
KMT2A Q03164 9/20 0.69
MAPT P10636 2/20 0.66
KDM4E B2RXH2 1/20 0.66
RXFP1 Q9HBX9 2/20 0.66
CYP3A4 P08684 1/20 0.65
PTGS1 P23219 1/20 0.65
RECQL P46063 2/20 0.64
CTDSP1 Q9GZU7 1/20 0.64
TDP1 Q9NUW8 1/20 0.64
CA1 P00915 1/20 0.64
USP2 O75604 1/20 0.62
LMNA P02545 1/20 0.62
HTT P42858 1/20 0.62
L3MBTL1 Q9Y468 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17689190 0.86 MEN1 (0.79) ALDH1A1POLBMEN1KMT2AMAPT
SCHEMBL13212157 0.84 KMT2A (0.68) ALDH1A1POLBMEN1KMT2AMAPT
SCHEMBL13212122 0.83 KMT2A (0.67) ALDH1A1POLBMEN1KMT2AMAPT
SCHEMBL13056445 0.82 MEN1 (1.00) ALDH1A1POLBMEN1KMT2AMAPT
SCHEMBL13212127 0.82 PTPN1 (0.80) ALDH1A1POLBMEN1KMT2AMAPT
SCHEMBL13212137 0.82 MEN1 (0.79) ALDH1A1POLBMEN1KMT2AMAPT
SCHEMBL15116292 0.82 KMT2A (0.79) ALDH1A1POLBMEN1KMT2AMAPT
SCHEMBL13212119 0.81 KMT2A (0.67) ALDH1A1POLBMEN1KMT2AMAPT
SCHEMBL15116268 0.81 KMT2A (0.71) ALDH1A1POLBMEN1KMT2AMAPT
SCHEMBL15116290 0.81 KMT2A (0.74) ALDH1A1POLBMEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130184258-A1 Compositions Useful as Inhibitors of Voltage-Gated Sodium Channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-07-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130184258-A1 Compositions Useful as Inhibitors of Voltage-Gated Sodium Channels SCNN1G, KCNN3, KCNN2 ALDH1A1 2811/4885POLB 4241/4885MEN1 2329/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.